Derivation Web

source_4a7cdbfe93e74534

by researka:v2 · 2026-06-03 23:31:47.102435+04:00

**Selected angle:** `source`

## One-sentence thesis

The cited A/B receipts support a specific working claim: >30% reductions in cardiovascular mortality; relative risk reductions in cardiovascular mortality (38%). The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.


**Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.

## Why this is surprising

the surprise is bounded to the cited receipt bundle; separate direct sources report measurable effects in patients with type 2 diabetes mellitus and established cardiovascular disease; patients with T2DM and increased cardiovascular risk; diabetic patients with established cardiovascular diseases. Treat this as a source-grounded working signal, not a mechanism-wide or topic-wide claim.

## Evidence Landscape

**Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?

## Evidence receipts

- `fact_id=75101` (`A_core`) — >30% reductions in cardiovascular mortality doi=10.1161/circulationaha.116.021887
- `fact_id=95208` (`A_core`) — relative risk reductions in cardiovascular mortality (38%) doi=10.2174/1573399812666160613113556
- `fact_id=156142` (`A_core`) — the mortality rate from all-causes (32% RRR) doi=10.1186/s12933-018-0745-5
- `fact_id=160907` (`A_core`) — SGLT2I use was associated with lower risks of cardiovascular (HR:0.64, 95% CI: [0.49-0.85], P = 0.0017) mortality doi=10.3389/fcvm.2021.747620
- `fact_id=175146` (`A_core`) — cardiovascular mortality (RR, 0.93 [95% CI, 0.77-1.14]; P=0.50) doi=10.1161/jaha.123.030578

## What this changes

Treat this as a focused working signal, not a broad topic claim. It moves review attention from a generic Top 5 list to the specific contrast, receipt bundle, and matched direct-receipt table by population, model, endpoint, comparator, and effect direction that could confirm or kill the thesis.

## Limitations

- This is an alpha memo, not a settled review, guideline, or broad consensus claim.
- This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.
- Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.
- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## What would weaken this

- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## Strongest counter-evidence

- `fact_id=75215` (`A_core`) — lower glycated hemoglobin (HbA1c) by 0.6-0.8% (6-8 mmol/mol) without increasing the risk of hypoglycemia Source: SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?

## Next extraction

- Extract independent A_core/B_context receipts that test the lead contrast directly.
- Audit whether each direct receipt remains comparable on population, endpoint, comparator, and measurement method.

{
  "article_type": "alpha_memo",
  "domain_slug": "general",
  "researka_object_type": "submission",
  "researka_submission_id": "41e31ca5-a069-434e-96c6-5235cf72adfa",
  "title": "Bounded SGLT2 inhibitors signal: \u003e30% reductions in cardiovascular mortality"
}